Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...

Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.

The Food and Drug Administration (FDA) has granted Fast Track designation to bempikibart for the treatment of alopecia areata (AA).

Discover management strategies for alopecia areata, from anti-inflammatory diets to stress reduction techniques that can help ...

When it comes to the world of hair loss, it’s no question that the amount of information out there can feel extremely ...

The European Medicines Agency (EMA) has recommended marketing authorization for Tepezza (teprotumumab) for adults with ...

Medically reviewed by Susan Bard, MD Alopecia areata is a common hair loss condition. It affects people of all ages, races, ...

AbbVie’s Rinvoq (upadacitinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with giant cell ...

Here, we analyse the evolving industry pipeline for autoimmune diseases, with a focus on emerging ... and the first JAK3/TEC inhibitor for alopecia (Litfulo; Pfizer) were also launched.

XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to ...

EMA recommends marketing approval for Amgen Europe’s Tepezza to treat adults with moderate to severe thyroid eye disease: Amsterdam, The Netherlands Monday, April 28, 2025, 11:0 ...

Elizabeth Sevigny reached rock bottom when her hair started to fall out, but everything changed when she had a baby and ...